Krish Patel, MD

Shared insight on the future of diffuse large B-cell lymphoma management, highlighting unmet needs and hope for continued growth in the treatment landscape.

Jason Westin, MD, and expert panelists highlight additional clinical data presented at the 2023 American Society of Hematology annual meeting.

With the emergence of newer agents, panelists discuss their approaches to best sequence treatments for patients with R/R DLBCL.

A comprehensive overview of safety considerations for bispecific antibodies in patients treated for R/R DLBCL.

Experts transition their discussion to highlight the emergence of bispecific antibodies as an additional treatment option for patients with R/R DLBCL.

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options.

Krish Patel, MD, discusses the latest advances in the treatment of non-Hodgkin’s lymphoma and how fixed-duration treatment options can improve the overall patient experience.

Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses emerging therapeutic strategies and ongoing research in mantle cell lymphoma (MCL).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses zanubrutinib in the treatment of patients with mantle cell lymphoma.

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses induction therapy in patients with mantle cell lymphoma (MCL).

Krish Patel, MD, medical oncologist, Swedish Cancer Institute, discusses a study looking at real-world benefit of BTK inhibitors versus what is seen in clinical trials for patients with mantle cell lymphoma.

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses the promise of acalabrutinib in the treatment of patients with mantle cell lymphoma.

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).